Scientific Co-Founder Dr. Ben Barres
We’re passionate about bringing game-changing therapies to patients suffering from serious complement-mediated autoimmune, neurodegenerative and ophthalmic disorders
Dr. Ben Barres discovered that C1q drives synapse loss and disease progression in neurodegenerative disorders and co-founded Annexon together with Dr. Arnon Rosenthal who helped develop ANX005
C1q also known to drive tissue damage in antibody-mediated autoimmune disease
Completed Series A financing
Developed ANX005 and other classical pathway inhibitors (C1q, C1s, C2, C4)
Demonstrated importance of inhibiting C1q at the top of the pathway, blocking activity before it starts
ANX005: clinical POC in GBS as lead antibody-mediated autoimmune indication
ANX007: Full target engagement in the eye with intravitreal administration in glaucoma patients
Annexon’s IPO spurs pipeline and organizational growth
ANX009: Full target engagement in the blood space with subcutaneous administration in healthy volunteers
ANX005: Completed enrollment in first Phase 3 pivotal program for GBS in 40 years and granted Orphan Drug Designation by the EMA.
ANX007: Demonstrated statistically significant, dose-dependent preservation of visual function in Phase 2 trial of ANX007 in GA patients
ANX1502: Achieved target pharmacokinetics in Phase 1 healthy volunteer study of ANX1502
Late-stage clinical pipeline of therapies with the potential to provide functional benefit for complement-mediated diseases of the body, brain and eye.
Our proven and passionate leadership team has a successful track record of discovering, developing and commercializing breakthrough therapeutics for the disease indications we are pursuing. We are deeply committed to leveraging our science to develop novel C1q inhibitors for the treatment of patients with complement-mediated diseases of the body, brain and eye.
CHIEF EXECUTIVE OFFICER
EVP & CHIEF INNOVATION OFFICER
EVP & CHIEF MEDICAL OFFICER
CHIEF SCIENTIFIC OFFICER
EVP & CHIEF FINANCIAL OFFICER
EVP & CHIEF BUSINESS OFFICER
Annexon’s Board of Directors is comprised of accomplished leaders in biotechnology and investments, with expertise in corporate governance, research and development, commercialization and finance.
BOARD CHAIR BOARD CHAIR, FORMER FOUNDER, CHAIRMAN & CEO DERMIRA
BOARD MEMBER CHIEF BUSINESS AND STRATEGY OFFICER GLOBAL BLOOD THERAPEUTICS
PRESIDENT & CEO ANNEXON
BOARD MEMBERMANAGING PARTNERSATTER INVESTMENT MANAGEMENT
PROFESSOR AND CHAIR OF OPHTHALMOLOGY, BYERS EYE INSTITUTE, STANFORD UNIVERSITY
ROBERT A. FISHMAN DISTINGUISHED PROFESSOR CHAIR, DEPARTMENT OF NEUROLOGY, UCSF
PROFESSOR AND CHAIRMAN, DEPARTMENT OF NEUROLOGY, WASHINGTON UNIVERSITY SCHOOL OF MEDICINE
CHAIR, DEPARTMENT OF BIOCHEMISTRY, COLUMBIA UNIVERSITY
ASSISTANT PROFESSOR NEUROLOGY, CHILDREN’S HOSPITAL BOSTON, HARVARD MEDICAL SCHOOL
PROFESSOR OF NEUROLOGY, UNIVERSITY OF GLASGOW